Biopharmaceutical company NanoBio Corporation announced on Monday a change in corporate name to BlueWillow Biologics to reflect its evolution to a vaccines-focused company as well as its commitment to advancing its novel intranasal technology to develop new vaccines for several diseases.

Additionally, the company has completed a USD10m Series A financing led by North Coast Technology Investors, Line Moon Ventures and the University of Michigan through its MINTS initiative.

Headquartered in Ann Arbor, Michigan, BlueWillow Biologics® is a privately-held biopharmaceutical company, focused on developing and commercializing intranasal vaccines using its patented NanoVax technology platform. The technology employs a novel oil-in-water nanoemulsion adjuvant that is effective when administered via intranasal or intramuscular vaccination, and can elicit both mucosal and systemic immunity when applied intranasally.

Currently, BlueWillow is developing intranasal vaccines for several respiratory and sexually transmitted infections, including RSV, pertussis, influenza, anthrax, prophylactic and therapeutic HSV-2 and chlamydia.

Concurrently, BlueWillow will continue to develop skin and wound treatments through partnerships and external collaborations under the prior NanoBio trademark.